Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group
Authors:
- Shigemitsu HorieSHShigemitsu Horie
- Sei NaitoSNSei Naito
- Shingo HatakeyamaSHShingo Hatakeyama
- Shuya KandoriSKShuya Kandori
- Kazuyuki NumakuraKNKazuyuki Numakura
- Renpei KatoRKRenpei Kato
- Tomoyuki KoguchiTKTomoyuki Koguchi
- Shingo MyoenSMShingo Myoen
- Yoshihide KawasakiYKYoshihide Kawasaki
- Akihiro ItoAIAkihiro Ito
- Hisanobu AdachiHAHisanobu Adachi
- Yoshiyuki KojimaYKYoshiyuki Kojima
- 22 September 2023
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 28 (11) , 1538-1544
Abstract
Background The Modified International Metastatic Renal Cell Carcinoma Dataset Consortium model (mIMDC) is a preoperative prognostic model for pT3cN0M0 renal cell carcinoma (RCC). This study aimed to validate the mIMDC and to construct a new model in a localized and locally advanced RCC (LLRCC). Methods A database was established (the Michinoku Japan Urological Cancer Study Group database) consisting of 79 patients who were clinically diagnosed with LLRCC (cT3b/c/4NanyM0) and underwent radical nephrectomy from December 2007 to May 2018. Using univariable and multivariable analyses, we retrospectively analyzed disease-free survival (DFS) and overall survival (OS) in this database, constructed a new prognostic model according to these results, and estimated the model fit using c-index on the new and mIMDC models. Results Independent poorer prognostic factors for both DFS and OS include the following: ≥ 1 Eastern Cooperative Oncology Group performance status, 2.0 mg/dL C-reactive protein, and > upper normal limit of white blood cell count. The median DFS in the favorable (no factor), intermediate (one factor), and poor-risk group (two or three factors) was 76.1, 14.3, and 4.0 months, respectively (P < 0.001). The 3-year OS in the favorable, intermediate, and poor-risk group were 92%, 44%, and 0%, respectively (P < 0.001). The c-indices of the new and mIMDC models were 0.67 and 0.60 for DFS (P = 0.060) and 0.74 and 0.63 for OS (P = 0.012), respectively. Conclusion The new preoperative prognostic model in LLRCC can be used in patient care and clinical trials.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patientsWorld Journal of Urology, 2016
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialThe Lancet, 2016
- Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based studyWorld Journal of Urology, 2016
- Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyTargeted Oncology, 2015
- Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorsInternational Journal of Clinical Oncology, 2012
- Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 PatientsEuropean Urology, 2010
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Multi-Institutional Validation of a New Renal Cancer–Specific Survival NomogramJournal of Clinical Oncology, 2007
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003
- A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMAJournal of Urology, 2001